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Abstract
BACKGROUND: Renal cancers account for around 3% of all 
cancers and the most common type of (90%) is renal cell car-
cinoma Five-year survival rate in renal cancer patients is 68.4%.
AIM: The aim of our study was to establish the role of 
F18-FDG-PET/CT in restaging patients with renal carcinoma who 
underwent partial or radical nephrectomy. Secondary aim of the 
study was to identify histological characteristics of the primary 
tumour that may be responsible for the metabolic behaviour of 
neoplastic lesions.
MATERIALS AND METHODS: We retrospectively evaluated 
68 patients with renal carcinoma in whom F18-FDG-PET/CT 
was performed.
RESULTS: Sensitivity, specificity, positive predictive value, 
negative predictive value and accuracy of F18-FDG PET/CT were 
82%, 100%, 100%, 66.7% and 86.8%, respectively.
CONCLUSIONS: The results of our study suggest that F18-FDG 
PET/CT is characterised by high specificity and positive predic-
tive value and can be useful in restaging patients affected by 
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renal carcinoma. However, due to low negative predictive value, 
this method cannot be recommended for definitely ruling out 
suspected disease relapse. 
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Background
Renal cancers account for around 3% of all cancers [1] and the 
most common type (90%) is renal cell carcinoma (RC) [2]. Five-year 
survival rate in renal cancer patients is 68.4% all over the globe [3]. 
RC has been shown to be resistant to radiation therapy and chemo-
therapy [4], therefore radical or partial nephrectomy remains the 
mainstay of treatment for the localized disease [5]. Although 
patients with RC localized in the kidney are treated with surgery 
and have a favourable prognosis [5], 20–40% will later develop 
metastases and the 5-year survival decreases to below 10% [6]. 
Furthermore, 20–30% of the patients already have metastatic 
disease at the time of diagnosis [7]. The most common sites for 
the recurrences are the lung and regional lymph nodes followed 
by bone, liver and brain [8]. In the past, treatment of metastatic 
RC (MRC) was limited to interferon-a, interleukin-2, cytoreductive 
surgery, and palliative radiation therapy, but recently therapy with 
sunitinib, sorafenib [9, 10], multiple tyrosine kinase inhibitors (mul-
tiple TKIs) targeting vascular endothelial growth factor receptor 
(VEGFR), and everolimus [11] has been proposed as new options. 
Ultrasonography (US), contrast enhanced computed tomography 
(CECT) and magnetic resonance imaging (MRI) are commonly used 
imaging modalities for the detection of RC recurrences, providing 
morphological details. Prognosis in RC depends on tumour extent, 
presence of metastasis and other prognostic factors, like age, 
general state of health, and co-morbidities. Unfortunately there 
is no specific laboratory parameter useful and reliable as a tumour 
marker for RC [12, 13]. The primary aim of our study was to estab-
lish the role of F18-FDG PET/CT in restaging patients affected by 
RC who underwent partial or radical nephrectomy. The reference 
standard was considered histology of the lesions, when available, 
or clinical evaluation plus all radiologic studies performed (CECT, 
MRI, US). Secondary aim of the study was to identify histological 
characteristics of the primary tumour that may be responsible for 
the metabolic behaviour of neoplastic lesions and, consequently, 
for F18-FDG-PET/CT results. 
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Materials and methods
From August 2005 to July 2011, about 9600 patients were 
evaluated and 14800 PET/CT studies were performed in our depart-
ment of Nuclear Medicine. Among this large group of patients, only 
in 68 (49 male [72%] and 19 female [28%]; median age: 68 ± 4 
years) had a diagnosis of renal carcinoma (confirmed after surgical 
intervention). We retrospectively evaluated these patients. In par-
ticular, 62 patients (91%) underwent total nephrectomy and 6 (9%) 
partial nephrectomy. Data regarding histological subtype of renal 
carcinoma was available in 52 patients (76.5%); a clear cell renal 
cell carcinoma was diagnosed in 44 patients (64.7%), a chromo-
phobe renal cell carcinoma in 4 (5.8%), a papillary cell carcinoma 
in 3 (4.5%), and a collecting ducts (Bellini) carcinoma in 1 (1.5%); 
for the remaining 16 patients (23.5%) the histological subtype data 
was not available. According to Fuhrman grading score (available 
for all 44 patients with clear cell carcinoma) of primary tumour [14], 
no patient was classified as G1, 12 patients (27%) were classified 
as G2, 15 patients (34%) as G3 and 17 patients (39%) as G4. 
All patients underwent F18-FDG PET/CT examination in order 
to restage the disease due to clinical suspicion of disease relapse 
or during routine follow-up. The reference standard to assess PET 
diagnostic accuracy was considered histology of secondary le-
sions (available in 10 patients) or the sum of clinical and all radio-
logical data available (CECT, MRI, US). Moreover, 11 patients after 
the first F18-FDG PET/CT examination underwent a second study 
to assess response to systemic therapy with sunitinib or sorafenib 
or to local radiation therapy.
F18-FDG PET/CT was performed after at least 6 hours fast-
ing and with the glucose level lower than 150mg/dl. FDG dose 
of 5.5 MBq/Kg was administered intravenously and a 2D mode 
ordered-subset-expectation-maximization (OS-EM) imaging (with 
septa) was acquired 60 minutes after injection from the skull ba-
sis to the mid-thigh on a Discovery ST PET/CT tomograph (General 
Electric Company — GE® — Milwaukee, WI, USA) with standard 
CT parameters (80 mA, 120 Kv without contrast; 4 minutes per 
bed-PET-step of 15 cm). The reconstruction was performed in 
a 128 × 128 matrix and 60 cm field of view. The patients were 
instructed to void before imaging. The PET images were analysed 
visually and semi-quantitatively by measuring the maximum 
standardized uptake value (SUVmax). SUV was expressed as 
SUVbody weight (SUVbw — g/ml) and automatically calculated by 
the software (Volumetrix for PET/CT; Xeleris™ Functional imaging 
workstation; GE) on the basis of following parameters: weight of 
the patient expressed in kilograms; height expressed in centime-
tres; tracer volume expressed in ml; radioactivity at injection time 
expressed in MBq; post injection activity in the vial expressed in 
MBq; injection time; starting time acquisition; decay half-time of 
the radioisotope (standard 109.8 minutes for F18-FDG). A written 
consensus was obtained from all patients before every study. 
Images readout was performed on a Xeleris™ Functional 
imaging workstation (GE®) and the reader had knowledge of the 
clinical history. Every focal tracer uptake deviation from physiologi-
cal distribution was considered as suggestive of diseases while 
faint bilateral tracer uptake in inguinal, axillary and pulmonary hilar 
lymph-nodes was considered as being inflammatory. No specific 
SUV-value cut-off was adopted to discriminate benign from ma-
lignant lesions. Instead, the diagnostic criterion was the deviation 
from physiological distribution and background or from the normal 
tissue activity around the suspect lesion. No respiratory gating 
was performed. 
Results
F18-FDG PET/CT imaging was negative in 27 patients (39.7%) 
and positive in 41 (60.3%). Widespread metastases involving 
at least three organs (bone, lungs, lymph nodes etc.) were re-
vealed in 14 patients (34.2%) (Figure 1, 2), lung metastases in 12 
(29.3%) patients, lymph nodes metastases in 8 (19.5%), lymph 
nodes plus lungs in 3 (7.3%), bone metastases in 3 (7.3%) (Fig-
ure 3), adrenal gland metastases in 1 (2.4%) patient. In the group 
of patients classified as G2 according to Fuhrman grading score, 
F18-FDG PET/CT was negative in 8 patients (67%) and positive in 
4 (33%); in the group G3 it was negative in 8 (53%) and positive in 
7 (47%) patients; in the group G4 it was negative in 6 (35%) and 
positive in 11 (65%) patients. In the group of patients affected by 
clear cell renal cell carcinoma, F18-FDG PET/CT was negative 
in 17 patients (39%) and positive in 27 (61%); in the group of 
chromophobe cell carcinoma it was negative in all; in the group 
of papillary cell carcinoma it was negative in 1 patient (34%) and 
positive in 2 (66%) patients; in the patient affected by collecting 
ducts (Bellini’s) carcinoma it was positive; in the group of unknown 
subtype of renal carcinoma it was negative in 5 patients (31%) and 
positive in 11 (69%) patients. F18-FDG PET/CT results according 
to Fuhrman score and histological subtype are summarised in 
Table 1. No significant statistical correlation was observed between 
F18-FDG PET/CT results and Furhman grade or histology type of 
primary tumour at contingency tables (p > 0.05) despite increasing 
the Fuhrman grade the percentage of positive studies increases. 
Sensitivity, specificity, positive predictive value, negative predictive 
value and accuracy of F18-FDG PET/CT were 82%, 100%, 100%, 
66.7% and 86.8%, respectively.
In all patients who underwent biopsy of the lesions revealed at 
PET/CT, a renal carcinoma metastases were documented. In par-
ticular, in 3 patients with bone lesions, F18-FDG PET/CT revealed 
pathological findings that were not detected by CECT; the diagno-
sis was confirmed by histological examination after biopsy. Among 
the 11 patients who underwent a second study after therapy, F18-FDG 
PET/CT showed a disease progression in 4 patients (36%), partial re-
sponse in 3 (28%) and stable diseases in 4 (36%); no patients showed 
a complete response. Disease progression was defined as a pres-
ence of new lesions and/or higher uptake of the previous metastatic 
site according to European Organization for Research and Treatment 
of Cancer (EORTC) criteria [15]; using the same criteria, partial re-
sponse was defined as a presence of uptake reduction or disappear-
ance of some lesions in absence of new lesions.
Discussion
Accurate restaging and, particularly, detection of metastatic 
sites of RC are crucial for the management of patients, because 
this can lead to modifying therapeutic strategies and serve as an in-
dication for surgery, radiotherapy, or systemic treatment. Despite 
the fact that the widespread application of US has increased the 
number of incidentally detected renal tumours, this method has lim-
ited utility in identifying retroperitoneal disease, venous tumour 
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thrombus extension, and metastasis. MRI has some advantages, 
including multi-planar imaging, high resolution, and lack of ra-
diation exposure, but takes a long time to perform, has limited 
whole-body imaging capability (necessity to change both patient 
position and surface coils), and limited accuracy in demonstrating 
lung metastases. During treatment and follow-up, patients with RC 
are generally monitored with chest radiograph, CECT and, possibly, 
MRI to assess the shrinkage or increase of lesions, the burden of 
Figure 1. Maximum intensity projection (MIP) images of a patient with widespread metastatic disease who underwent F18-FDG PET/CT before  
(1-A1) and after (1-A2) systemic therapy. The study revealed a significant disease progression and no response to therapy
Figure 2. Maximum intensity projection (MIP) images of a patient with widespread metastatic disease who underwent F18-FDG PET/CT before 
(2-A1) and after (2-A2) systemic therapy with sunitinib. The study revealed uptake reduction in all sites of disease previously detected but showed 
new lesions at left internal mammary lymph node chain. Axial fused images of the left humerus before (2-B1) and after (2-B2) the treatment 
revealing partial response
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the disease [16] and the efficacy of treatment, in terms of stable dis-
ease, regression or progression, according to the Response Evalu-
ation Criteria in Solid Tumours (RECIST) [17]. CECT represents the 
mainstay of cross-sectional imaging in RC, with a sensitivity of up 
to 100% and specificity exceeding 90% for retroperitoneal disease, 
venous tumour thrombus, and metastasis. Recommendations to 
optimize detection of visceral metastasis of RC include scanning 
the abdomen and pelvis first, in the arterial phase, followed by 
scanning of the chest from the lung apices through the liver and 
kidneys. Although CECT radiation dose increases as a result of 
thin collimation, over-beaming, and over-ranging, dose modulation 
software that decreases radiation necessary to obtain a certain 
contrast-to-noise ratio in the CECT image data when body diameter 
decreases is commercially available [18].
Since the introduction of F18-FDG PET/CT, a new option and 
diagnostic opportunity has been available for patients affected by 
RC. Despite it has been proved to be useful in revealing incidental 
congenital renal and ureteric anomalies in patients studied for 
neoplastic reasons [19, 20], it is well known and accepted that 
F18-FDG PET/CT has low sensitivity for the diagnosis of primary 
RC because of renal excretion of the F18-FDG [21–24]. In fact it 
has not greatly improved the management of primary renal cancer 
because the specificity and sensitivity of this technique seem to be 
less effective than CECT and because primary renal tumours could 
express low levels of glucose transporters such as GLUT-1, which 
are responsible for the accumulation of F18-FDG [21]. On the con-
trary, although there are limited data available, its role for detection 
of recurrent RC seems promising and some papers have shown 
good sensitivity and specificity ranging from 63 to 88% and 75 to 
100%, respectively [21, 22, 25–29]. 
F18-FDG PET without CT has often demonstrated modest ac-
curacy for metastatic RC, with positive studies being suspicious, 
while negative studies not reliably excluding disease [26] and be-
ing too unreliable to recommend its routine use in the restaging of 
RC. Most studies have been performed using PET while only few 
studies, like ours, with PET/CT [22, 25–28, 30–32]. Park et al. [31] 
have shown that sensitivity, specificity and accuracy of F18-FDG 
PET/CT scanning in detecting recurrent RC is 89.5%, 83.3% and 
85.7%, respectively. Kumar et al have analysed 63 patients who 
underwent 103 PET/CT scans with a sensitivity of 90%, specificity 
of 91%, and accuracy of 90% in diagnosing recurrent disease [32]. 
The most important studies and diagnostic performances of PET 
and PET/CT are summarised in table 2. Our data are in concord-
ance with literature, in particular with those studies performed with 
PET/CT [31, 32], which is the current technologic standard; it’s well 
established that PET/CT is superior than PET alone giving higher 
Figure 3. Images of bone metastases in a patient: axial fused (3-A1) and CT (3-A2) of left clavicular lesion, axial fused (3-B1) and CT (3-B2) of 
dorsal vertebra lesion and coronal fused (3-C1), sagittal fused (3-C2) and axial fused (3-C3) images of acetabular lesion (crosses)
Table 1. PET/CT results according Fuhrman grade and histology of 
primary tumor
Fuhrman Grade PET/CT  
positive (%)
PET/CT  
negative (%)
1 – –
2 4 (33) 8 (67)
3 7 (47) 8 (53)
4 11 (65) 6 (35)
Histology of primary tumor PET/CT  
positive (%)
PET/CT  
negative (%)
Clear-cell renal cell carcinoma 27 (61) 17 (39)
Chromophobe cell carcinoma – 4 (100)
Papillary cell carcinoma 2 (66) 1 (34)
Collecting ducts carcinoma 1 (100) –
Unknown histological subtype 11 (69) 5 (31)
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specificity and reducing false positive results. Compared with a very 
high specificity and positive predictive value (on average higher than 
those published in literature), our results suffer from a sub-optimal 
sensitivity and low negative predictive value. The most common 
cause for a false-negative result is microscopic disease, in fact it 
takes a certain number (104–107) of tumour cells with increased 
abnormal glucose metabolism to be detected by PET/CT imaging. 
Most of our diagnostic failures of PET occurred in lungs and liver. In 
fact PET technology even if equipped with CT for anatomic localisa-
tion and attenuation correction, could fail to correctly assess small 
lung metastases smaller than 5 mm; it is unclear whether this drop 
in sensitivity may be due to pulmonary motion artefacts or to a lower 
metabolic activity of lung metastases. The use of respiratory-gating 
and time-of-flight technology (TOF) [33] may improve diagnostic 
accuracy by reducing motion artefacts, blurring, “smearing effect”, 
and allowing a better spatial resolution; this could ensure a higher 
accuracy and a more precise SUV calculation, but no dedicated 
studies have been published on this specific topic. Moreover, our 
data showed that PET results are not related to Fuhrman score 
or histological type of primary tumour in concordance with those 
reported in other studies [28, 30]. 
An interesting field of application of F18-FDG PET/CT seems to 
be the therapy response evaluation [34]; it has been suggested to 
assess early response to tumour angiogenesis inhibitor drugs by 
means of FDG-PET, since both soft tissue and bone metastasis of 
RC demonstrate decrease of uptake in therapy responders after 
one to two months of treatment [34]. Katani et al have prospectively 
studied 44 patients by three sequential scans performed to deter-
mine if the timing of the investigation was relevant (before treatment, 
after 4 and 16 weeks); they concluded that baseline F18-FDG 
PET/CT yields prognostic significant data and responses occur in 
the majority of patients after 4 weeks of therapy; however it’s not 
until 16 weeks when the results become prognostically significant 
[35]. Despite a very small number of patients, in our study therapy 
response evaluation has been documented as feasible and useful 
for clinical management.
A critical issue is the histological confirmation of pathologic 
findings revealed by PET/CT to effectively establish and confirm 
the presence of relapsed disease, which has to be theoretically 
considered the gold standard. Unfortunately, in daily practice, 
this is seldom possible because of clinical reasons, feasibility of the 
procedure and effective advantages of this approach in absence 
of a radical surgical intent. In our study histological confirmation 
was available in 10 patients and all the other ones were com-
pared with clinical plus radiological findings. It’s interesting that in 
3 cases bone metastases were revealed at F18-FDG PET/CT and 
confirmed at histological examination in presence of negative 
CECT. Despite the very small number of cases, this could suggest 
a possible added value of metabolic imaging, responsible for 
an increased detection rate of bone metastases frequently present 
in patients affected by RC. A systematic confrontation between 
the two methods in a larger series of patients would be desirable 
in order to confirm or controvert this insight also considering that 
traditional nuclear medicine diagnostic tools in this field are mainly 
based on bone scintigraphy with technetium-99m methylene di-
phosphonate, characterised by limited accuracy. In a prospective 
study, Sohaib et al. [36] have recently compared MRI and bone 
scintigraphy diagnostic performances in 47 patients obtaining 
high levels of specificity in both methods (97% and 94% respec-
tively) but significantly different sensitivity values (94% for MRI vs. 
62% for bone scan). Wu et al have compared F18-FDG PET and 
technetium-99m methylene diphosphonate bone scan document-
ing higher sensitivity and accuracy of positron imaging in detecting 
bone metastases in patients affected by RC [37]. The major limits of 
bone scan seem to be the low sensitivity, especially for small le-
sions, and that the evaluation is limited to bone. 
Conclusions
In conclusion, despite the limitations of our study due to the 
retrospective type of analysis and the absence of systematic 
histological confirmation of pathological uptake, our results are in 
agreement with literature and suggest that F18-FDG PET/CT is cha-
racterised by high specificity and positive predictive value and could 
be useful in restaging patients with renal carcinoma. This method 
could be very useful in detecting bone metastases and in therapy 
monitoring, but cannot be recommended for definitely ruling out 
suspected disease relapse, due to its low negative predictive value. 
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